Trivascular Technologies (NSDQ:TRIV) shares made a good showing on their first day on the Nasdaq stock exchange, having gained 15% by about 4 p.m. EST.
Stent Grafts
Lombard Medical tables U.S. IPO
Lombard Medical Technologies (LON:LMT) said today that it’s tabling a planned initial public offering on the NASDAQ exchange due to adverse conditions in the U.S. stock market.
TriVascular Technologies sets price range for $98M IPO
TriVascular Technologies said it could raise as much as $98 million from its planned initial public offering after setting the per-share price range at $13-$15.
That would set the top end of the 6.5-million-share offering at $97.5 million, or $84.5 million at the low end.
Lombard Medical sets range for $55m – $65M IPO
Lombard Medical Technologies (LON:LMT) today set the range for its forthcoming U.S. initial public offering, saying it plans to price its shares between $15 apiece and $18.
TriVascular Tech aims for $100M IPO
California medical device maker TriVascular Technologies is looking to raise as much as $100 million through its initial public offering, the details of which have yet to be finalized.
Gore’s Viabahn stent graft bests angioplasty, study finds
Arizona medical device maker W.L. Gore & Assoc. teased positive results from its REVISE clinical trial, promising to release additional findings during the American Society of Diagnostic & Interventional Nephrology meeting in Phoenix this week.
Cordis releases 2-year data from Incraft stent trial
Cordis Corp, a Johnson & Johnson (NYSE:JNJ) subsidiary, released 2-year data from its INNOVATION trial testing the safety and performance of the Incraft abdominal aortic aneurysm stent graft system.
Medtronic lands expanded FDA approval for Valiant Captivia
London’s Lombard Medical seeks U.S. IPO
TriVascular adds $2M in options round
TriVascular Inc. sold $1.9 million in an options offering, adding to a $40 million Series E funding round it logged last month.
Santa Rosa, Calif.-based TriVascular makes the Ovation line of stent grafts for treating abdominal aortic aneurysms.
The company sold options and convertible notes to 2 unnamed investors, according to a regulatory filing.
Gore appeals $860M loss to Bard
C.R. Bard (NYSE:BCR) had no standing to bring the patent infringement lawsuit that won it a nearly $860 million verdict against W.L. Gore & Assoc., Gore argued in its appeal yesterday.